EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

Curating evidence-based lifestyle recommendations is key to achieving ideal cardiometabolic health in patients with obesity, ...

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

Danish pharmaceutical giant Novo Nordisk has introduced its type 2 diabetes treatment, Ozempic, in India. Positioned as a ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...

A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

A study has found that the obesity treatment 'Wegovy' from Danish pharmaceutical company Novo Nordisk has also influenced ...

The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.